

GGTI298 Trifluoroacetate

Catalog No: tcsc7690



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

1217457-86-7

Formula:

$C_{29}H_{34}F_3N_3O_5S$

Pathway:

GPCR/G Protein

Target:

Ras

Purity / Grade:

>98%

Solubility:

DMSO : 150 mg/mL (252.67 mM; Need ultrasonic and warming)

Observed Molecular Weight:

593.66


Product Description

GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (**GGTase I**) inhibitor, which can inhibit **Rap1A** with **IC₅₀** of 3 μ M; little effect on **Ha-Ras** with **IC₅₀** of >20 μ M.

IC50 & Target: IC50: 3 μ M (Rap1A, in vivo), > 20 μ M (Ha-Ras, in vivo)^[3]

In Vitro: RhoA inhibitor (GGTI298 Trifluoroacetate) significantly reduces cAMP agonist-stimulated apical K⁺ conductance^[1]. Knockdown of DR4 abolishes NF- κ B activation, leading to sensitization of DR5-dependent apoptosis induced by the combination of GGTI298 Trifluoroacetate and TRAIL. GGTI298 Trifluoroacetate/TRAIL activates NF- κ B and inhibits Akt. Knockdown of DR5, prevents GGTI298/TRAIL-induced I κ B α and p-Akt reduction, suggesting that DR5 mediates reduction of I κ B α and p-Akt induced by GGTI298/TRAIL. In contrast, DR4 knockdown further facilitates GGTI298/TRAIL-induced p-Akt reduction^[2].

In Vivo: The vivo mouse ileal loop experiments show fluid accumulation is reduced in a dose-dependent manner by TRAM-34, GGTI298 Trifluoroacetate, or H1152 when inject together with cholera toxin into the loop^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!